Enveric Biosciences (NASDAQ: ENVB) is pioneering non-hallucinogenic therapies called neurostabilogens. With FDA guidance fast-tracking its lead candidate EB-003, Enveric is positioning itself as a scalable, practical alternative to first-wave psychedelic treatments.
